Annual General Meeting Details
Shareholders in Swedish Orphan Biovitrum AB (publ) (Sobi) are invited to attend the upcoming Annual General Meeting (the "Meeting"). The Board of Directors confirms that the shareholders can exercise their voting rights at the Meeting via postal voting if they cannot attend in person.
Registration and Participation
In-Person Attendance
If you wish to join the Meeting in person or by proxy, it's essential to be listed as a shareholder in the register prepared by Euroclear Sweden AB. Shareholders must give notice of participation before the stipulated deadline to ensure their voices are heard in the discussions.
Voting by Proxy
Should you appoint a proxy to represent you at the Meeting, a written and dated power of attorney is required. This document must be signed by the shareholder to be valid. Proxy forms can be obtained from the company's website, ensuring that everything is in order for a smooth representation.
Postal Voting Options
For those choosing to vote by post, registering your intent to do so is mandatory. Complete the postal voting form and submit it according to the instructions outlined prior to the deadline. It's crucial to ensure that no specific conditions or instructions accompany the postal vote, as such modifications can invalidate the voting process.
Nominee Registered Shares
Shareholders whose shares are registered in the name of a nominee must also perform a re-registration process to gain the right to participate in the Meeting. This step is vital to ensure that your interests are properly represented and that you are entitled to vote.
Proposed Meeting Agenda
The agenda for the Meeting includes significant topics, such as:
1. Election of the Meeting chair.
2. Approval of the voting list.
3. Presentation and approval of the annual report and auditor's report.
4. Adoption of the income statement and balance sheet.
5. Election of members to the Board of Directors and auditor.
Key Executive Elections
Notable proposals include re-appointments of current Board members and a fresh election for new candidates. These selections play a pivotal role in guiding Sobi towards its goals of delivering innovative treatments to patients.
Management and Employee Incentive Programs
The Board proposes the implementation of long-term incentive programs. This dual approach aims to benefit both management and all employees, fostering commitment and aligning employee interests with those of shareholders. The overarching goal of these programs is to enhance motivation across the entire workforce while supporting Sobi's growth strategy.
Costs and Financial Impact
The anticipated costs related to these incentive programs are meticulously calculated based on previous share pricing and employee participation projections. The aim is to ensure that such expenses remain manageable while delivering value to Sobi and its stakeholders.
Final Notes and Summary
As the Annual General Meeting approaches, shareholders are encouraged to review all pertinent documents available on the company's website. This includes reports, proposals, and guidelines that will aid in informed decision-making at the Meeting.
Sobi continues its mission as a leading biopharma company, committed to transforming the lives of individuals with rare diseases through innovative solutions. With dedicated employees and robust incentive schemes in place, Sobi looks forward to a fruitful future as they engage their shareholders collaboratively.
Frequently Asked Questions
What is the date of the Annual General Meeting?
The Annual General Meeting will take place on Thursday, 8 May 2025.
How can I participate in the Meeting?
Participation can be done in person, by proxy, or through postal voting.
What do I need to bring to the Meeting?
Shareholders should bring valid identification and any necessary documentation if attending by proxy.
Where can I find more information about the agenda?
Detailed information about the agenda can be found on Sobi's official website.
Are there any costs associated with the incentive programs?
The costs for the incentive programs will be disclosed in line with the financial reports.
